Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer

April 22, 2014

Join Philip Kantoff, MD, and Paul Nguyen, MD, as they present their multidisciplinary expertise on a range of cases pertaining to prostate cancer.

New evidence from multiple clinical trials may impact management of prostate cancer across the disease spectrum. For low-risk local tumors, Wilt et al reported similar survival in men randomized to surgery or observation, adding to the ongoing debate on the management of early tumors detected by PSA testing. With a median follow-up of 10 years, a phase III intergroup trial confirmed a significant survival advantage of adding radiation to androgen deprivation therapy in patients with locally advanced prostate cancer.  

For metastatic disease, a phase III randomized intergroup study found that the popular approach of intermittent hormone therapy shortens survival compared to continuous therapy. In addition to its approved use in the post-docetaxel setting, abiraterone acetate is also associated with favorable survival in chemotherapy-naïve patients in a new phase III study. Other therapies that have been approved based on randomized phase III data include sipuleucel-T, cabazitaxel, and denosumab. New agents continue to produce encouraging results in the treatment of castration-recurrent prostate cancer. Both the anti-androgen enzalutamide and radioactive agent alpharadin demonstrated improved survival in randomized clinical trials.

Oncologists, oncology nurses, and other clinicians who manage patients with prostate cancer face challenges in identifying the appropriate combination and sequence of treatments for all stages of prostate cancer. In patients with prostate cancer, the risk assessment status needs to be known, as well as the previous treatment history, prior to deciding on a treatment for the patient. It is increasingly critical for physicians to learn how to balance the risk of recurrence and the potential side effects of active treatment to guide patients in making informed, individualized decisions. Additionally, cryotherapy should be discussed with patients to determine most effective and appropriate use.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this webinar, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for prostate cancer in the treatment of patients
  • Describe the multidisciplinary aspects of patient management for prostate cancer
  • Identify the key characteristics for prostate cancer that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information

This activity is supported by educational grants from:

  • Daiichi Sankyo, Inc.
  • Genentech
  • Millennium: The Takeda Oncology Company
  • Novartis Pharmaceuticals Corporation
  • Teva Pharmaceuticals

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This activity is supported by a grant from Onyx Pharmaceuticals.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
Course expires: 
Event starts: 
04/22/2014 - 12:30pm EDT
Event ends: 
04/22/2014 - 1:30pm EDT

Philip W. Kantoff, MD
Dana-Farber/Brigham and Women’s Cancer Center

Paul Nguyen, MD
Dana-Farber/Brigham and Women’s Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing